阿奇霉素联合头孢噻肟钠对慢性阻塞性肺疾病患者肺功能的影响

Effect of Azithromycin combined with Cefotaxime Sodium on pulmonary function in patients with chronic obstructive pulmonary disease

目的探讨阿奇霉素联合头孢噻肟钠对慢性阻塞性肺疾病患者肺功能的影响。方法选取2017年4月~2018年4月深圳市蛇口人民医院收治的100例慢性阻塞性肺疾病患者作为此次研究工作的对象。应用随机抽签法将患者分为两组,即对照组与研究组,每组各50例。对照组患者采用常规基础治疗方法,研究组患者则在此基础上应用阿奇霉素联合头孢噻肟钠治疗。比较两组患者治疗前后的肺功能指标、治疗前后临床症状积分以及临床治疗效果。结果两组患者治疗前的用力肺活量(FVC)、最大通气量(MVV)、1 s用力呼气量(FEV1)比较,差异无统计学意义(P>0.05)。研究组患者治疗后的FVC为(2.40±0.45)L,MVV为(88.95±2.65)L/min,FEV1为(1.88±0.13)L,均高于对照组[(2.15±0.20)L、(80.10±1.15)L/min、(1.40±0.35)L],差异有统计学意义(P<0.05)。两组患者治疗前的慢性咳嗽咯痰、气短呼吸困难、喘息胸闷、疲乏消瘦积分比较,差异无统计学意义(P>0.05)。研究组患者治疗后的慢性咳嗽咯痰积分为(1.18±0.07)分,气短呼吸困难积分为(1.05±0.01)分,喘息胸闷积分为(1.18±0.06)分,疲乏消瘦积分为(1.38±0.04)分,均低于对照组[(1.85±0.05)、(2.21±0.05)、(2.03±0.07)、(1.96±0.07)分],差异有统计学意义(P<0.05)。研究组患者的临床治疗总有效率为96.00%,高于对照组(76.00%),差异有统计学意义(P<0.05)。结论慢性阻塞性肺疾病患者实施阿奇霉素联合头孢噻肟钠治疗的效果更显著,而且可以有效改善其肺功能指标、症状指标,有重要的临床应用价值。

Objective To investigate the effect of Azithromycin combined with Cefotaxime Sodium on pulmonary function in patients with chronic obstructive pulmonary disease.Methods One hundred patients with chronic obstructive pulmonary disease admitted to Shekou People's Hospital from April 2017 to April 2018 were selected as the subjects of this study,and were divided into the control group(n=50)and the study group(n=50)by random lottery.The control group was treated with conventional basic treatment,while the study group was treated with Azithromycin combined with Cefotaxime Sodium.The lung function indexes before and after treatment,the clinical symptom scores before and after treatment,and the clinical treatment effect were compared between the two groups.Results Before treatment,there were no significant differences in the forced vital capacity(FVC),maximum ventilator volume(MVV),and forced expiratory volume in 1 second(FEV1)between the two groups(P>0.05).After treatment,the FVC of patients of the study group was(2.40±0.45)L,the MVV was(88.95±2.65)L/min,and the FEV1 was(1.88±0.13)L,which were higher than those in the control group([2.15±0.20]L,[80.10±1.15]L/min,[1.40±0.35]L),the differences were statistically significant(P<0.05).Before treatment,there were no statistically significant differences in the scores of chronic cough and expectoration,shortness of breath,wheezing chest tightness,and fatigue and weight loss between the two groups(P>0.05).The score of chronic cough and expectoration after treatment was(1.18±0.07)points,the score of shortness of breath after treatment was(1.05±0.01)points,the score of wheezing chest tightness after treatment was(1.18±0.06)points,and the score of fatigue and weight loss after treatment was(1.38±0.04)points in the study group,all lower than those in the control group([1.85±0.05],[2.21±0.05],[2.03±0.07],[1.96±0.07]points),the differences were statistically significant(P<0.05).The total effective rate was 96.00%in the study group,which was higher than that in the control group accounting for 76.00%(P<0.05).Conclusion The treatment of Azithromycin combined with Cefotaxime Sodium in patients with chronic obstructive pulmonary disease is more effective,can effectively improve the lung function index and symptom index,and has important clinical application value.